GLP-1 Action 10 mg, 60 caps

Orforglipron is an innovative, orally administered substance in laboratory studies that supports the fight against type 2 diabetes and helps with weight loss. It works by suppressing appetite and improving blood sugar control for better health and weight management. The unique formula is based on an action similar to other modern medicines for this ailment, but in a convenient tablet form, eliminating the need for injections. Early studies indicate high efficacy and safety, making Orforglipron an important part of therapy for people struggling with diabetes and excess weight.

Acting as a GLP-1 receptor agonist, it was developed as a stable organic compound that can be effectively administered orally. The non-peptide nature provides resistance to enzymatic degradation, including lack of susceptibility to the DPP-4 enzyme, resulting in better bioavailability.

Mode of action:

• May help lower blood sugar levels when they are too high, such as after eating.
• It can reduce appetite and slow the rate of gastric emptying, so people can eat less and lose weight more easily.
• It can support the work of the pancreas, which is responsible for producing insulin, a hormone that helps maintain normal sugar levels.
• According to clinical studies, the good bioavailability of the non-peptide structure of the compound in oral form
• May help lower blood sugar, which is crucial for the health of people with diabetes.
• May aid weight loss and weight control, which is important for heart health and overall fitness.
• May improve well-being and reduce the risk of diabetes-related complications, such as heart or kidney disease.
  
  

Clinical findings and statistics

• Reduction in blood glucose levels - in clinical trials, reductions in HbA1c of up to 2.1% have been achieved at appropriate doses.
• Weight loss - study participants reported weight loss of 10 to as much as 13 kg in 46-75% of participants after 36 weeks of use, making it a strong candidate for treating obesity.
• Reduction in waist circumference - up to 8.7 cm in clinical trials.
• Improvement in metabolic/cardiometabolic parameters - studies show beneficial effects on indicators related to cardiovascular risk in obese individuals.

Tolerability and possible side effects during Orforglipron studies
In the results of published clinical trials, the most commonly reported adverse symptoms in people taking Orforglipron were gastrointestinal complaints such as nausea, diarrhea, vomiting and constipation. These were usually mild to moderate in nature. These symptoms were more common than in the placebo groups, and were particularly associated with the dose escalation phase of the multi-dose studies.

The product is intended for research and laboratory analysis purposes. All information provided on this site is for informational and educational purposes only.